Lipocine Analyst Price Targets - Benzinga

Lipocine Inc

LPCNNASDAQ

Trade with Public

Trade with Public

$1.44

-0.02-1.37%

Ult. Agg.: Oct 23, 7:14 PM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Rapporto azionario

Lipocine Analyst Price Targets - Benzinga

Lipocine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lipocine (LPCN).

Price Target Range — 6 Quarters

Analyst Consensus — 2 Analysts

1Buy

1Hold

Consensus RatingBuy# Analysts2Avg. Consensus PT$7Upside to Avg. PT+386.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 21, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Neutral	$4
Apr 6, 2026	HC Wainwright & Co.	Yi Chen	Downgrade	Buy→Neutral	—
Jan 21, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$7→$15
Nov 13, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$8→$7
Aug 20, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$8
Jun 27, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$8
Jun 10, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$8
May 29, 2025	HC Wainwright & Co.	Yi Chen	Assumes	Buy	$8
Sep 24, 2024	Alliance Global Partners	Scott Henry	Initiate	Buy	$10

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Neutral and announces $4 price target.

Benzinga Newsdesk

What's Going On With Carvana Stock Monday?

BofA downgrades Carvana (CVNA) to Neutral, cutting the price target to $360. Explore the latest analyst insights and technical support levels.

Lekha Gupta

This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Wall Street analysts changed their outlook on top names. Check out the ratings page for complete changes. Check out what analysts think about CVNA.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Lipocine to Neutral

HC Wainwright & Co. analyst Yi Chen downgrades Lipocine (NASDAQ:LPCN) from Buy to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lipocine, Raises Price Target to $15

HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and raises the price target from $7 to $15.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lipocine, Lowers Price Target to $7

HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers the price target from $8 to $7.

Benzinga Newsdesk